



COLLEGE OF
NATUROPATHIC PHYSICIANS
OF BRITISH COLUMBIA

Re: Update - IV Curcumin

In May 2017, the College placed a moratorium on the initiation of any new patients to intravenous (IV) curcumin. This was due to the reports concerning the death of a 30-year-old woman in California on March 2017 after administration of an IV curcumin product. On May 1, 2017, FDA received another adverse event report concerning a 71-year-old male patient who developed a hypersensitivity reaction after the administration of an IV curcumin product compounded by the same company. It was determined that the inactive ingredient used in compounding this product was ungraded and not suitable for human consumption; the ingredient used in error by the company had likely led to the two serious adverse outcomes. No other major adverse reactions from IV curcumin were reported since these two events. This moratorium was a temporary measure until the College could perform further research to ascertain safe sourcing of and methodology for the IV administration of curcumin.

After considerable review and effective June 05, 2024, the Board lifted the moratorium on IV Curcumin. Registrants were notified in the legacy college (College of Naturopathic Physicians of BC) newsletter in June 2024. The college wishes to remind registrants of their responsibility to meet all professional obligations under the Bylaws, Codes of Conduct and Ethics, Professional Standards, ND Scope of Practice Standards, Limits, Conditions and various Standards of Practice.